O. Fedorov - Concepedia

Author

O. Fedorov

Also Known As

F. von Delft, Fedorov, Oleg, N.B. La Thangue, O. Fedorov, O. King, O. Yu. Fedorov, Oleg Fedorov, Oleg Y. Fedorov, T. Chen

160

Publications

11.8K

Citations

H-Index

Concepts

All Affiliations

University of Oxford Genomics (United Kingdom)Genomics England University of Cambridge Ludwig Cancer Research

About

O. Fedorov is an author at University of Oxford specializing in medicine, natural sciences, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	29	8.1K
2	Natural Sciences	21	23	2.9K
3	Biochemistry	13	14	1.7K
4	Biomolecular Engineering	2	2	111
5	Biostatistics	1	1	43

O. Fedorov

Publications

11.7K

Citations

H-Index

Page 1

	Year	Citations
Selective inhibition of BET bromodomains P. Filippakopoulos, Jun Qi, S. Picaud, Nature Bet BromodomainsGeneticsPathogenesisMolecular GeneticsMedicine	2010	4.2K
Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination Masoud Vedadi, F. Niesen, Abdellah Allali‐Hassani, Proceedings of the National Academy of Sciences New LigandsProtein AssemblyMolecular BiologyChemical BiologyProtein Crystallization	2006	589
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain S. Picaud, Christopher Wells, I. Felletar, Proceedings of the National Academy of Sciences	2013	475
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases O. Fedorov, Brian D. Marsden, Vanda Pogačić, Proceedings of the National Academy of Sciences	2007	375
Dual kinase-bromodomain inhibitors for rationally designed polypharmacology Pietro Ciceri, Susanne Müller, Alison O’Mahony, Nature Chemical Biology Molecular PharmacologyMedicinal ChemistryMedicineDual Kinase-bromodomain InhibitorsRational Drug Design	2014	347
The (un)targeted cancer kinome O. Fedorov, Susanne Müller, Stefan Knapp Nature Chemical Biology Tumor BiologyOncologyMedicineCancer GenomicsTumor Suppressor	2010	308
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses Ariane Hammitzsch, C. Tallant, O. Fedorov, Proceedings of the National Academy of Sciences	2015	252
PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains S. Picaud, David Da Costa, Angeliki Thanasopoulou, Cancer Research Histone ModificationsChemoprevention StrategyBet BrdsMolecular BiologyBet Proteins	2013	244
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy S. Picaud, O. Fedorov, Angeliki Thanasopoulou, Cancer Research	2015	224
3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands David S. Hewings, Minghua Wang, Martin Philpott, Journal of Medicinal Chemistry Histone ModificationsMolecular BiologyOrganic ChemistryChemical BiologyMolecular Pharmacology	2011	222

Page 1